Monte Rosa Therapeutics Inc (GLUE) - Net Assets
Based on the latest financial reports, Monte Rosa Therapeutics Inc (GLUE) has net assets worth $245.84 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($459.84 Million) and total liabilities ($214.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GLUE financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $245.84 Million |
| % of Total Assets | 53.46% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 25.14 |
Monte Rosa Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Monte Rosa Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Monte Rosa Therapeutics Inc for the complete picture of this company's asset base.
Annual Net Assets for Monte Rosa Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Monte Rosa Therapeutics Inc from 2019 to 2024. For live valuation and market cap data, see market value of Monte Rosa Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $222.94 Million | +24.37% |
| 2023-12-31 | $179.25 Million | -33.96% |
| 2022-12-31 | $271.41 Million | -21.90% |
| 2021-12-31 | $347.51 Million | +813.17% |
| 2020-12-31 | $-48.73 Million | -301.12% |
| 2019-12-31 | $-12.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Monte Rosa Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42639000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $-3.36 Million | -1.51% |
| Other Components | $664.87 Million | 298.24% |
| Total Equity | $222.94 Million | 100.00% |
Monte Rosa Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Monte Rosa Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IRSA Inversiones y Representaciones SA
BA:IRSA
|
$1.22 Billion |
|
Power HF Co Ltd
SHG:605100
|
$1.22 Billion |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
$1.22 Billion |
|
Tibet GaoZheng Explosive Co Ltd
SHE:002827
|
$1.22 Billion |
|
Hna-Caissa Travel Group Co Ltd
SHE:000796
|
$1.22 Billion |
|
Keystone Reit Ltd
TA:KSTN
|
$1.22 Billion |
|
Advantage Oil & Gas Ltd.
TO:AAV
|
$1.22 Billion |
|
Shanghai Prisemi Electronics Co Ltd
SHG:688230
|
$1.22 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Monte Rosa Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 179,250,000 to 222,936,000, a change of 43,686,000 (24.4%).
- Net loss of 72,700,000 reduced equity.
- Share repurchases of 641,000 reduced equity.
- New share issuances of 944,000 increased equity.
- Other comprehensive income decreased equity by 632,000.
- Other factors increased equity by 116,715,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-72.70 Million | -32.61% |
| Share Repurchases | $641.00K | -0.29% |
| Share Issuances | $944.00K | +0.42% |
| Other Comprehensive Income | $-632.00K | -0.28% |
| Other Changes | $116.72 Million | +52.35% |
| Total Change | $- | 24.37% |
Book Value vs Market Value Analysis
This analysis compares Monte Rosa Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.23x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.28 | $18.80 | x |
| 2020-12-31 | $-1.11 | $18.80 | x |
| 2021-12-31 | $7.47 | $18.80 | x |
| 2022-12-31 | $5.75 | $18.80 | x |
| 2023-12-31 | $3.49 | $18.80 | x |
| 2024-12-31 | $3.02 | $18.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Monte Rosa Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -96.14%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.97x
- Recent ROE (-32.61%) is below the historical average (-28.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.80 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.01 Million |
| 2021 | -21.28% | 0.00% | 0.00x | 1.05x | $-108.71 Million |
| 2022 | -39.98% | 0.00% | 0.00x | 1.26x | $-135.64 Million |
| 2023 | -75.51% | 0.00% | 0.00x | 1.69x | $-153.28 Million |
| 2024 | -32.61% | -96.14% | 0.17x | 1.97x | $-94.99 Million |
Industry Comparison
This section compares Monte Rosa Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Monte Rosa Therapeutics Inc (GLUE) | $245.84 Million | 0.00% | 0.87x | $1.22 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more